Cretinism medical therapy: Difference between revisions
Jump to navigation
Jump to search
| (5 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Cretinism}} | {{Cretinism}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}} {{AEL}} | ||
==Overview== | ==Overview== | ||
The mainstay of treatment for cretinism is thyroid hormone replacement therapy. [[levothyroxine]] (L-T4) is administrated orally to patients with cretinism. | |||
The mainstay of treatment for | |||
[ | |||
==Medical Therapy== | ==Medical Therapy== | ||
*Patients with cretinism are treated with thyroid hormone replacement therapy. | *Patients with cretinism are treated with thyroid hormone replacement therapy. | ||
*Endocrine society recommended with the appropriate quick initiation of levothyroxine as the mainstay treatment of cretinism.<ref name="pmid24446653">{{cite journal| author=Léger J, Olivieri A, Donaldson M, Torresani T, Krude H, van Vliet G et al.| title=European Society for Paediatric Endocrinology consensus guidelines on screening, diagnosis, and management of congenital hypothyroidism. | journal=J Clin Endocrinol Metab | year= 2014 | volume= 99 | issue= 2 | pages= 363-84 | pmid=24446653 | doi=10.1210/jc.2013-1891 | pmc=4207909 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24446653 }}</ref> | *Endocrine society recommended with the appropriate quick initiation of [[levothyroxine]] as the mainstay treatment of cretinism.<ref name="pmid24446653">{{cite journal| author=Léger J, Olivieri A, Donaldson M, Torresani T, Krude H, van Vliet G et al.| title=European Society for Paediatric Endocrinology consensus guidelines on screening, diagnosis, and management of congenital hypothyroidism. | journal=J Clin Endocrinol Metab | year= 2014 | volume= 99 | issue= 2 | pages= 363-84 | pmid=24446653 | doi=10.1210/jc.2013-1891 | pmc=4207909 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24446653 }}</ref> | ||
* | *'''[[Levothyroxine]]:''' | ||
**Life long synthetic [[levothyroxine]] (L-[[T4]]) is used to treat the cretinism. | |||
**Preferred regimen: 10–15 μg/kg per day orally. | |||
==References== | ==References== | ||
| Line 56: | Line 18: | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
| |||
[[Category:Medicine]] | |||
[[Category:Endocrinology]] | |||
[[Category:Up-To-Date]] | |||
| |||
[[Category:Pediatrics]] | |||
Latest revision as of 15:04, 30 October 2017
|
Cretinism Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Cretinism medical therapy On the Web |
|
American Roentgen Ray Society Images of Cretinism medical therapy |
|
Risk calculators and risk factors for Cretinism medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Elsaiey, MBBCH [2]
Overview
The mainstay of treatment for cretinism is thyroid hormone replacement therapy. levothyroxine (L-T4) is administrated orally to patients with cretinism.
Medical Therapy
- Patients with cretinism are treated with thyroid hormone replacement therapy.
- Endocrine society recommended with the appropriate quick initiation of levothyroxine as the mainstay treatment of cretinism.[1]
- Levothyroxine:
- Life long synthetic levothyroxine (L-T4) is used to treat the cretinism.
- Preferred regimen: 10–15 μg/kg per day orally.
References
- ↑ Léger J, Olivieri A, Donaldson M, Torresani T, Krude H, van Vliet G; et al. (2014). "European Society for Paediatric Endocrinology consensus guidelines on screening, diagnosis, and management of congenital hypothyroidism". J Clin Endocrinol Metab. 99 (2): 363–84. doi:10.1210/jc.2013-1891. PMC 4207909. PMID 24446653.
Template:WH Template:WS